Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Linus Haberbosch, James MacFarlane, Olympia Koulouri, Daniel Gillett, Andrew S Powlson, Sue Oddy, David J Halsall, Kevin A Huynh, Jonathan Jones, Heok K Cheow, Joachim Spranger, Knut Mai, Christian Strasburger, Richard J Mannion, Mark Gurnell
BACKGROUND: L-[methyl-11C]-methionine-positron emission tomography (Met-PET) is a potentially important imaging adjunct in the diagnostic workup of pituitary adenomas, including somatotroph tumours. Met-PET can identify residual or occult disease and make definitive therapies accessible to a subgroup of patients who would otherwise require lifelong medical therapy. However, existing data on its use are still limited to small case series. Here, we report the largest single centre experience (N=61) in acromegaly...
March 14, 2024: European Journal of Endocrinology
#2
REVIEW
Ilan Shimon
Cabergoline is an ergot derivative long-acting dopamine receptor 2 (DR2) selective agonist administered orally and widely used for the treatment of prolactin-secreting adenomas and Parkinson's disease. DR2 is expressed in most somatotroph adenomas. In acromegaly, cabergoline is used off-label and its role is limited by the relatively modest efficacy for achieving hormonal remission and thus, it is largely indicated in patients with mild elevation of GH/IGF-I postoperatively. It can be given as monotherapy, usually at a higher weekly dose than usually required to treat prolactinomas, but also as an add-on treatment in patients partially responding to the somatostatin receptor ligands octreotide or lanreotide...
February 28, 2024: Best Practice & Research. Clinical Endocrinology & Metabolism
#3
JOURNAL ARTICLE
Marta Araujo-Castro, Betina Biagetti, Edelmiro Menéndez Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich, Rogelio García Centeno, Laura González, María Dolores Ollero García, Ana Irigaray Echarri, María Dolores Moure Rodríguez, Cristina Novo-Rodríguez, María Calatayud, Rocío Villar, Ignacio Bernabéu, Cristina Alvarez-Escola, Pamela Benítez Valderrama, Carmen Tenorio-Jimenéz, Pablo Abellán Galiana, Eva Venegas Moreno, Inmaculada González Molero, Pedro Iglesias, Concepción Blanco, Fernando Vidal-Ostos De Lara, Paz de Miguel, Elena López Mezquita, Felicia Hanzu, Iban Aldecoa, Cristina Lamas, Silvia Aznar, Anna Aulinas, Anna Calabrese, Paola Gracia, José María Recio-Córdova, Mariola Aviles, Diego Asensio-Wandosel, Miguel Sampedro, Ignacio Ruz-Caracuel, Rosa Camara, Miguel Paja, Carmen Fajardo-Montañana, Mónica Marazuela, Manel Puig-Domingo
PURPOSE: To evaluate differences in clinical presentation and in surgical outcomes between growth hormone-secreting pituitary adenomas (GH-PAs) and GH and prolactin co-secreting pituitary adenomas (GH&PRL-PAs). METHODS: Multicenter retrospective study of 604 patients with acromegaly submitted to pituitary surgery. Patients were classified into two groups according to serum PRL levels at diagnosis and immunohistochemistry (IHC) for PRL: a) GH&PRL-PAs when PRL levels were above the upper limit of normal and IHC for GH and PRL was positive or PRL levels were >100ng/and PRL IHC was not available (n=130) and b) GH-PAs who did not meet the previously mentioned criteria (n=474)...
March 4, 2024: Journal of Clinical Endocrinology and Metabolism
#4
JOURNAL ARTICLE
Camilla M Falch, Kristin Godang, Tove Lekva, Thor Ueland, Ansgar Heck, Jens Bollerslev, Nicoleta C Olarescu
CONTEXT: Patients with active acromegaly present a decreased adipose tissue (AT) mass, and short-term studies show that treatment leads to AT depot-specific gain. However, it remains unclear if the increase is persistent in the long-term perspective and/or is sex-dependent. DESIGN: To characterize the depot-specific changes of AT after treatment of acromegaly and identify contributing factors. METHODS: Adipose tissue, including visceral (VAT), subcutaneous (SAT), and total (TAT), and android to gynoid ratio (A/G ratio) were measured by dual energy X-ray absorptiometry at diagnosis (n = 62), and after treatment at short-term (median (IQR) 1...
March 2, 2024: European Journal of Endocrinology
#5
JOURNAL ARTICLE
Nadia Sawicka-Gutaj, Aleksandra Derwich-Rudowicz, Aleksandra Biczysko, Solomiya Turchyn, Paulina Ziółkowska, Katarzyna Ziemnicka, Paweł Gut, Kacper Nijakowski, Marek Ruchała
Acromegaly is a chronic disease caused by the hypersecretion of growth hormone (GH), leading to changes in the growth of visceral tissues and glucose impairment. Serum biomarkers that correlate with disease status are still unclear. This study aims to assess the potential of phosphorus and calcium as biomarkers in the clinical evaluation of patients with acromegaly and clarify their relationship with SAGIT and other common biomarkers. We retrospectively analyzed data from 306 medical records of patients with acromegaly hospitalized between 2015 and 2020...
December 11, 2023: Biomedicines
#6
JOURNAL ARTICLE
Salomon Cohen Cohen, Rima Rindler, Edgar Botello Hernandez, Diane Donegan, Dana Erickson, Fredric B Meyer, John L Atkinson, Jamie J Van Gompel
OBJECTIVE: Transsphenoidal surgery (TSS) is considered the treatment of choice in most patients with growth hormone (GH)-secreting pituitary adenomas. Several preoperative factors have been studied to predict postsurgical remission. Our objective was to design a score that could be used in the preoperative setting to identify patients that will achieve long-term biochemical remission after TSS. METHODS: A retrospective analysis of consecutive patients with GH-secreting pituitary adenomas that underwent TSS in our institution from 2000-2015 who fulfilled prespecified criteria were included...
December 18, 2023: World Neurosurgery
#7
JOURNAL ARTICLE
X Wang, M J Fan, Y F Yu, X Y Fan, J Chen, Y F Lai, Y Liu, H Y Ye, Z Y Zhang, Y Zhao, Y F Wang, L H Xiang, M He, Y Ma
BACKGROUND: Acne vulgaris is a prevalent skin condition. We have found that some acromegaly patients have acne. However, no study has examined the relationship between acromegaly and acne. OBJECTIVE: To explore prevalence and correlation of adult acne in patients with acromegaly. METHODS: For this cross-sectional study, we collected questionnaires, clinical information, and laboratory test results of acromegaly patients from January 2022 to December 2022 at Huashan Hospital...
December 19, 2023: Journal of Endocrinological Investigation
#8
JOURNAL ARTICLE
L I Astafyeva, A N Shkarubo, I V Chernov, S R Ibrahim, I N Badmaeva, Yu V Strunina, I A Ilovayskaya, V S Pronin, Yu G Sidneva, P L Kalinin
BACKGROUND: Treatment of acromegaly is still an unresolved problem. Overall postoperative remission rate ranges from 34 to 85%. These values are better for microadenomas (75-90%) and worse for macroadenomas (45-70%). Identification of predictors of acromegaly remission after surgical treatment is an urgent objective to improve the quality of medical care for these patients. OBJECTIVE: To analyze postoperative freedom from acromegaly and predictors of remission. MATERIAL AND METHODS: A retrospective single-center study included 227 patients with acromegaly who underwent resection of pituitary adenoma between August 2018 and August 2021...
2023: Zhurnal Voprosy Neĭrokhirurgii Imeni N. N. Burdenko
#9
JOURNAL ARTICLE
Andrea Giustina, Nienke Biermasz, Felipe F Casanueva, Maria Fleseriu, Pietro Mortini, Christian Strasburger, A J van der Lely, John Wass, Shlomo Melmed
PURPOSE: The 14th Acromegaly Consensus Conference was convened to consider biochemical criteria for acromegaly diagnosis and evaluation of therapeutic efficacy. METHODS: Fifty-six acromegaly experts from 16 countries reviewed and discussed current evidence focused on biochemical assays; criteria for diagnosis and the role of imaging, pathology, and clinical assessments; consequences of diagnostic delay; criteria for remission and recommendations for follow up; and the value of assessment and monitoring in defining disease progression, selecting appropriate treatments, and maximizing patient outcomes...
November 3, 2023: Pituitary
#10
JOURNAL ARTICLE
Meiping Chen, Lian Duan, Hui Miao, Na Yu, Shengmin Yang, Linjie Wang, Fengying Gong, Yong Yao, Huijuan Zhu
PURPOSE: Acromegalic patients with giant growth hormone-secreting pituitary adenomas (GHPAs) (≥ 40 mm) are relatively rare, and their clinical characteristics and treatment outcome data are limited. This study aims to analyze the clinical practice experience of giant GHPAs. METHODS: Sixty-seven acromegalic patients with giant GHPAs and 67 patients with macro GHPAs (10-39 mm), matched for age and gender from the same hospital during the same period, were retrospectively recruited...
October 17, 2023: Pituitary
#11
JOURNAL ARTICLE
Martina Romanisio, Rosa Pitino, Alice Ferrero, Francesca Pizzolitto, Samuele Costelli, Valentina Antoniotti, Paolo Marzullo, Gianluca Aimaretti, Flavia Prodam, Marina Caputo
PURPOSE: The discrepancy between the biomarkers of disease's activity in acromegalic patients (GH and IGF-1) is almost frequent representing a challenge for the development of comorbidities in the long term. The aim of this study was to evaluate the prevalence and severity of metabolic comorbidities (diabetes, hypertension, and dyslipidemia) in surgically treated acromegalic patients with disease control and discordant GH and/or IGF-1 levels compared with those with concordant values...
2023: Frontiers in Endocrinology
#12
JOURNAL ARTICLE
Caiyan Mo, Han Chen, Fang Wang, Ying Guo, Yao Wang, Tao Tong, Liyong Zhong
OBJECTIVE: Few studies reported the effects of growth hormone-secreting pituitary adenoma (GHPA) on uric acid (UA) metabolism and the relationship between growth hormone (GH)/insulin-like growth factor-1 (IGF-1) levels and UA are controversial. This study aimed to evaluate the relationship between IGF-1 and UA in patients with GHPA and to further clarify whether UA levels are associated with GHPA disease activity by follow-up. METHODS: A longitudinal study of 424 GHPA patients presenting to Beijing Tiantan Hospital, Capital Medical University between January 2015 and January 2023 was conducted...
2023: Frontiers in Endocrinology
#13
RANDOMIZED CONTROLLED TRIAL
Natalya Vassilyeva, Natmir Mena, Kiril Kirov, Ekaterina Diatlova
INTRODUCTION: Somatotropinomas are the main cause of acromegaly. Surgery is the primary and most efficient method of treatment. The study aimed to compare the radicality of small-sized and medium (<30 mm) somatotropinoma removal and the incidence of postoperative complications in patients with acromegaly when using microscopic and endoscopic techniques. METHODS: In this randomized controlled trial, a total of 83 patients with acromegaly underwent transspheroidal endoscopy or microscopic surgery...
2023: Frontiers in Endocrinology
#14
JOURNAL ARTICLE
Camilla M Falch, Anne K Dupont, Nicoleta C Olarescu, Markus Wiedmann, Daniel Dahlberg, Jens Bollerslev, Jon Berg-Johnsen, Ansgar Heck
PURPOSE: Sustained cure of acromegaly can only be achieved by surgery. Most growth hormone (GH) secreting pituitary adenomas are macroadenomas (≥ 10 mm) at diagnosis, with reported surgical cure rates of approximately 50%. Long-term data on disease control rates after surgery are limited. Our aim was to estimate short- and long-term rates of biochemical control after pituitary surgery in acromegaly and identify predictive factors. METHODS: Patients operated for GH-secreting pituitary adenomas between 2005-2020 were included from the local pituitary registry (n = 178)...
September 4, 2023: Acta Neurochirurgica
#15
JOURNAL ARTICLE
Marinna C Okawa, Rebecca M Tuska, Marissa Lightbourne, Brent S Abel, Mary Walter, Yuhai Dai, Elaine Cochran, Rebecca J Brown
CONTEXT: Childhood overnutrition is associated with increased growth and bone mineral density (BMD), versus the opposite for undernutrition. The role of insulin receptor (InsR) signaling in these phenotypes is unclear. Rare disease patients with hyperinsulinemia and impaired InsR function (homozygous [-/-] or heterozygous [+/-] INSR pathogenic variants, Type B insulin resistance [TBIR]) vs patients with intact InsR function (congenital generalized lipodystrophy, CGL) model increased vs decreased InsR signaling...
August 18, 2023: Journal of Clinical Endocrinology and Metabolism
#16
JOURNAL ARTICLE
Ahmet Numan Demir, Cem Sulu, Zehra Kara, Serdar Sahin, Dilan Ozaydin, Ozge Sonmez, Fatma Ela Keskin, Necmettin Tanriover, Nurperi Gazioglu, Pinar Kadioglu
OBJECTIVE: Investigate the changes in the characteristics of presentation, in patients with acromegaly over a period of approximately half a century. METHODS: The medical records of patients diagnosed with acromegaly between 1980 and 2023 were retrospectively reviewed. The collected data were examined to assess any changes observed over the years and a comparison was made between the characteristics of patients diagnosed in the last decade and those diagnosed in previous years...
October 2023: Pituitary
#17
JOURNAL ARTICLE
Damla Tufekci, Irfan Nuhoglu, Sumeyye Sura Ayan, Yasemin Emur Gunay, Hulya Coskun, Muhammet Cuneyt Bilginer, Ozge Ucuncu, Mustafa Kocak, Serap Ozer Yaman, Suleyman Caner Karahan
PURPOSE: Acromegaly is closely related to increased oxidative stress and endothelial dysfunction (ED). This study aimed to evaluate, for the first time in the literature, signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) and endothelial nitric oxide synthase e(NOS) levels in the setting of acromegaly. METHOD: A total of 56 acromegaly patients and a control group composed of 30 healthy volunteers were included in this study. In the postoperative follow-up, patients were grouped as active or in-remission according to their GH and IGF-1 levels in oral glucose stimulation test (OGST)...
July 14, 2023: Endocrine
#18
JOURNAL ARTICLE
Rodrigo Alves de Carvalho Cavalcante, Luiz Alves Vieira, Luís Felipe Araújo Peres, Alice Jardim Zaccariotti, Helioenai de Sousa Alencar, Estela Muszkat Jatene, Leandro Azevedo Camargo, Monike Lourenço Dias Rodrigues
OBJECTIVE: The primary aim is to analyze the endoscopic endonasal surgical results in short-term and two-year follow-ups according to the 11th Acromegaly Consensus statement (2018). Indeed, prognostic factors and complications were analyzed. SUBJECTS AND METHODS: 40 patients who underwent endoscopic endonasal surgery by acromegaly between 2013 to 2020 was analyzed. Patients were considered in remission if an upper limit of normal (ULN) IGF-1 was less than 1.0 at the six-month and two-year follow-ups...
June 19, 2023: Archives of Endocrinology and Metabolism
#19
JOURNAL ARTICLE
Agata Popielarz-Grygalewicz, Maria Stelmachowska-Banaś, Dorota Raczkiewicz, Izabella Czajka-Oraniec, Grzegorz Zieliński, Wacław Kochman, Marek Dąbrowski, Wojciech Zgliczyński
BACKGROUND: Despite the preserved LVEF, patients with acromegaly are characterized by subclinical systolic dysfunction i.e., abnormal global longitudinal strain (GLS) assessed by speckle tracking echocardiography (STE). The effect of acromegaly treatment on LV systolic function assessed by STE, has not been evaluated so far. PATIENTS AND METHODS: Thirty-two naïve acromegalic patients without detectable heart disease were enrolled in a prospective, single-center study...
2023: Frontiers in Endocrinology
#20
JOURNAL ARTICLE
Xue-Qing Zheng, Xiang Zhou, Yong Yao, Kan Deng, Hui You, Lian Duan, Hui-Juan Zhu
PURPOSE: To retrospectively summarize the clinical features of acromegaly complicated with fulminant pituitary apoplexy and analyze the prognostic factors to guide early identification and timely treatment of such patients. METHODS: A retrospective analysis was carried out to summarize the clinical manifestations, hormone changes, imaging, treatment and follow-up of ten patients with acromegaly complicated with fulminant pituitary apoplexy admitted to our hospital from February 2013 to September 2021...
May 17, 2023: Endocrine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
